Abstract: Stem cells have been considered as a useful tool in Regenerative Medicine due to two main properties: high rate of self-renewal, and their potential to differentiate into all cell types present in the adult organism. Depending on their origin, these cells can be grouped into embryonic or adult stem cells. Embryonic stem cells are obtained from the inner cell mass of blastocyst, which appears during embryonic day 6 of human development. Adult stem cells are present within various tissues of the organism and are responsible for their turnover and repair. In this sense, these cells open new therapeutic possibilities to treat degenerative diseases such as type 1 diabetes. This pathology is caused by the autoimmune destruction of pancreatic β-cells, resulting in the lack of insulin production. Insulin injection, however, cannot mimic β-cell function, thus causing the development of important complications. The possibility of obtaining β-cell surrogates from either embryonic or adult stem cells to restore insulin secretion will be discussed in this review.
Abbreviations

Introduction
Stem cells can proliferate indefinitely in culture and, under certain circumstances, differentiate toward a committed lineage [1] . Asymmetric divisions with differential segregation of diverse molecules generate both differentiating and self-renewing daughter cells [2] . When these properties are considered together, stem cells could be considered as unlimited biological sources for therapeutic cell replacement approaches [3] . In addition, the use of emerging technologies, such as nuclear transfer [4] [5] [6] [7] [8] , oocyte parthenogenesis [9, 10] and cell reprogramming [11, 12] , are useful tools that may revolutionize the Regenerative Medicine field. Once these techniques become available, the generation of immunocompatible tissues for therapeutic trials will be more feasible.
The main objective of Regenerative Medicine is to generate customized tissues that allow the recovery of the lost function in the organism without immune rejection or tumor formation. Currently, however, the possibility of generating entire organs in vitro is impossible. At present, the obtainment of specific cell types seems to be a more realistic goal. In this context, the pathologies affected by the dysfunction of a specific cell type would be the first candidates to benefit from cell therapy protocols. This includes neurodegenerative pathologies, cardiovascular complications and osteoarticular diseases [13, 14] .
Type 1 diabetes can be included in this group of pathologies [15] . This disorder is caused by an autoimmune attack of pancreatic β-cells, the only cell in the adult organism that is responsible for insulin production and its subsequent secretion. This cell type is located inside a larger structure named as endocrine pancreas. The pancreas is a heterogeneous organ comprised of an exocrine portion (99%) involved in food digestion, and a small endocrine part (1%) formed by the islets of Langerhans. The latter are microorgans that contain several cell types, including α-cells, β-cells, δ-cells and PPcells. Each cell type is specialized in the production and secretion of a specific hormone: α-cells express glucagon, β-cells express insulin, δ-cells express somatostatin and PPcells produce pancreatic polypeptide. There are 1 million islets per adult pancreas, each containing approximately 2000 cells, the majority (60%) being β-cells [15] . Recently, a new population of ghrelin-expressing cells (epsilon-cells) has been characterized in rat and mouse pancreatic tissue [16] . Ghrelin is a ligand for the growth hormone secretagogue receptor and is produced by adult endocrine stomach cells. These cells share the same lineages as α and PP-cells. The developing pancreas seems to be responsible for the presence of circulating ghrelin in the fetus, maintaining fetal β-cells silenced during the prenatal period and avoiding hypoglycemic episodes [16, 17] . On the other hand, the exocrine pancreas is composed of acinar cells that secrete different types of hydrolytic enzymes involved in the digestion of lipids, carbohydrates and proteins present in the diet. The exocrine pancreas is also composed of the ductal system, which is involved in the delivery of digestive enzymes to the duodenum. In addition, ductal cells can secrete mucins and bicarbonate that are also delivered to the duodenum [18] .
Insulin is a key hormone in nutrient homeostasis, controlling glucose and fatty acid circulating levels as well as favoring the uptake of these molecules by peripheral tissues. There are no compensatory hormones that can mimic insulin function, forcing diabetic patients to intake the hormone from exogenous sources by daily injections. The absence of insulin leads to overt diabetes and death. Daily injection has made this disease manageable, but the problem is still far from solved. The maintenance of correct glucose levels, although beneficial, requires very well-trained and motivated patients in order to diminish glycemic fluctuations and the appearance of secondary complications, such as neuropathy, nephropathy, retinopathy and diverse cardiovascular disorders [15, 19] .
In addition to the general type 1 diabetes pathology commented, there are other rarer forms of idiopathic origin, even though in the majority of these cases there is an autoimmune origin. Antibodies against β-cell proteins such as surface antigens (antiislet), glutamate decarboxylase and tyrosin phosphatase have been described [20, 21] .
The pathology displays two phases: insulinitis, in which leukocytes invade the islets, and overt diabetes, in which the majority of the β cells are destroyed. In this situation there is not enough insulin to regulate circulating glucose levels and thus the patients require insulin injections to survive. Diagnosis is based on several symptoms characteristic of insulin absence such as hyperglycemia, polyphagia, weight loss (due to an increased catabolism of fat and proteins), polyuria, compensating polydipsia and ketoacidosis [15] .
The precise origin of the disease remains unknown, although it is believed that several environmental factors are capable of activating the autoimmune mechanisms in genetically predisposed individuals. Among them, we have to consider viral infections (coxsakie B-4, cytomegalovirus (CMV)), very early introduction of cow's milk to childrens' diets and toxins present in some foods, such as nitrates and nitrites. Exposure to the diabetogenic agent streptozotocin, a toxin produced by certain strains of Streptomyces, as well as to the antibiotic bafilomycin A1, could be implicated in the origin of the disease. Among the genetic factors, the HLA-DR3 phenotype found in Caucasians, as well as HLA-DR4, are related to type 1 diabetes [22] . In any case, the incidence of developing this pathology in a child when a parent is affected by the disease is only 10%, suggesting that the hereditary component is not playing such an important role [21] . On the other hand, type 2 diabetes represents a more complex pathology, which affects the 95% of diabetic patients. Several different factors influence the development of the disease, such as genetic predisposition, inflammation, obesity and overweight and sedentary life styles. In contrast to type 1 diabetes, type 2 diabetes can be delayed or prevented at early stages by adequate pharmacological and nutritional intervention together with increased physical activity. There are two related manifestations associated with the development of the disease: insulin resistance and β-cell failure by apoptosis. Excess of circulating nutrients, mainly glucose and fatty acids, play a critical role in progression of both cases [15] .
Type 1 diabetes appears early in life while type 2 is most prevalent in adults. Recent evidence indicates, however, that 5 − 15% of patients initially diagnosed with type 2 have an autoimmune diabetes form of slow progression termed LADA or latent autoimmune diabetes in adults [15, 23] .
As stated above, there is no definitive cure for diabetes. Insulin injection does not restore the exquisite regulation that β-cells exert on glucose homeostasis. Therefore, replacement of the damaged organ (i.e. islets) by transplantation seems to be a logical strategy, and this approach has been recently considered for the treatment of diabetes.
Transplantation of islets of Langerhans from cadaveric donors has been a proposed approach to treat diabetes. Recently, an improved transplantation protocol was developed by Dr. Shapiro´s group in Edmonton (Canada), which presents several advantages with respect to the classical double transplant of kidney and whole pancreas [24] . Islet transplantation results in the manipulation of a smaller tissue mass compared to the whole pancreas, resulting in several apparent advantages that allow the optimization of the procedure. Furthermore, islet transplantation requires minimally invasive surgery (percutaneous transhepatic portal embolization) compared to whole pancreas transplantation. Very often two pancreases are necessary to treat one recipient; this is due, in part, to the procedure to figure the optimal number of islets to be implanted in each particular recipient. In this sense, better adjustment of the β-cell mass correlated to plasma C-peptide and suppression of variations in fasting glycemia rather than to islets equivalents, result in standardized grafts yielding optimal cell function after transplantation [25] .
Other disadvantages that the islet transplantation presents are unsolved problems in order to establish a degree of security similar to what is found in other transplantation protocols, such as the kidney or heart. The main obstacle of the Edmonton's protocol is the immune rejection. This protocol uses sirolimus, tacrolimus and daclizumab, which are immunosuppressors that seem to have less deleterious effects in islet survival than cyclosporine, azatioprine and glucocorticoids, classically used for whole pancreas transplantation [24, 26] . However, the 5-year follow-up for all transplanted patients indicated that at the end only 10% maintained independence from insulin injections [27] . The causes of this failure were mainly attributed to side effects of the immunosuppressive therapy. Therefore, it remains to establish the long-term effects of these immunosuppressors on islet survival and function. Aside from immunity recurrence, other causes to consider in order to improve the Edmonton protocol are better adjustment of the number of islets in each particular patient, difficulties in monitoring the implant in the liver and the appearance of inflammatory processes [28] .
Although the Edmonton protocol is considered a hallmark in cell therapy for diabetes mellitus, improvements are required in order to find a correct immunosuppressive protocol, allowing long term standing of the allograft.
Nevertheless, the major drawback impairing the current development of any transplantation protocol, especially concerning islets, is the scarcity of cadaveric pancreata. Even in Spain, which ranks the number one country in organ donations, only 2000 pancreata per year would be available under the best of circumstances for islet isolation and subsequent transplantation. In order to cover the necessities of the majority of Spain´s type 1 diabetic patients, this figure needs to be increased 50-fold. Thus, new cell sources for replacement protocols must be found. In this context, stem cells offer an open possibility that, according to recent publications, deserves to be explored.
Stem cells
Depending on their origin, stem cells can be categorized into embryonic stem cells (ESCs) and adult stem cells (ASCs). ESCs are obtained from the inner cell mass of the blastocyst, which appears during embryonic day 6 in humans and 3.5 in mice (Table 1) [14] . ASCs are present within tissues of the adult organism and are responsible for their turnover or repopulation in normal or exceptional circumstances [29] . The main characteristics of both cell types are their ability to proliferate indefinitely in vitro and, under certain culture conditions, their potential to differentiate into various specific cell lineages. However, the proliferation potential seems to be more limited in the case of ASCs when compared to ESCs. In addition, ESCs present more plasticity in terms of differentiation, obtaining all cell types present in the adult organism, including β-cells. Despite this potential, ESCs do not seem to be the ideal source to generate insulin-secreting cells in vitr o. Published reports provide incomplete data supporting this idea, where for example, the possibility of tumor formation due to totipotent cells that escape the differentiation protocols represents a serious obstacle that need to be taken into account [30] .
In addition, the use of human ESCs still poses an ethical dilemma that could be circumvented by alternative technology, which includes nuclear transfer, parthenogenesis, isolation of one single cell from morula stage or reprogramming of adult cells by cell fusion techniques [31] . Cell fusion seems to raise less ethical problems. Nuclear transfer experiments have demonstrated that factors present in egg cytoplasm have the ability to turn-on a nucleus from a differentiated cell into a pluripotent stage. However, in vitro cell fusion experiments between a mature and a stem cell revealed that the factors necessary to differentiate an adult cell are residing into the nucleus rather than the cytoplasm of the stem counterpart [32] . Resulting cells are tetraploid and at present little evidence has been accumulated about the functional characteristics of these cells. Meanwhile, ASCs seem to be committed to specific cell fates. This is why ESCs are considered pluri/totipotent cells and ASCs are multipotent cells. However, the possibility that ASCs could cross cell-lineage limits by transdifferentiation mechanisms could offer interesting possibilities [33] . The main obstacles to this approach, which could constrain their clinical applications, are the following: discerning the transdifferentiation process from the cell fusion phenomena, difficulty of purifying these cells from certain tissues, and finally in order to maintain them in culture outside of their natural tissue niches, avoiding oncogenic gene activation. On the other hand, ASCs have a notorious advantage over ESCs in terms of immune compatibility, if an auto-transplant is considered. The potential to generate insulin-producing cells for cell therapy in diabetes from both cell types is explained in further detail below.
Adult stem cells
As mentioned before, ASCs represent an important alternative for cell replacement protocols in terms of immune compatibility. No ethical debate has been raised concerning the use of these cells, making them a priority choice to consider in Regenerative Medicine [34] . Concerning the pancreas, we have to consider two types of ASCs: pancreatic stem cells and extra-pancreatic stem cells.
Pancreatic stem cells
Several locations have been proposed as possible niches for pancreatic stem cells, such as the ducts, islets and acini. However, the identity of the potential progenitors located in these niches is still a matter of debate, which includes derivatives of the duct-epithelium, mesenchyme, acinar tissue and the β-cells.
Several studies have reported that pancreatic ducts bear stem cells with the potential to differentiate in vitro into islet-like structures. Several authors consider that the islet progenitors are located in the pancreatic duct, and have been classified as CHIBs (Cultivated Human Islet Buds) [35] , IPSCs (Islet Pluripotent Stem Cells) [36] and NIPs (Nestin-positive Islet-derived Progenitors), which are also found associated with islet structures [37] . However, in the majority of the studies the ductal-derived cells display variable amounts of insulin and glucagon content and poor secretory capacity. In any case, duct epithelium can be easily purified from cadaveric pancreata due to its exceptional ability to adhere to a broad range of surfaces, allowing a direct purification from the rest of the pancreatic cell types such as islets and exocrine tissue. This could favor subsequent manipulations that can improve the hormone content and the exocytotic response of ductal-derived cells, and offers a new potential application of human ductal tissue obtained from cadaveric pancreata.
NIPs, which were also associated with islets structures, were isolated from rat and human islets displaying a proliferative activity, expressing endocrine and exocrine pancreatic markers as well as hepatic genes [37] . Nestin has been described as a neural stem cell marker, though this gene is also expressed in mesenchymal cells present in the developing and adult human and mice pancreases [38] . Whether nestin is present in all the pancreatic progenitors is still in debate, although it seems to be expressed during in vitro expansion of isolated mouse pancreatic precursors [39, 40] . The role of nestin is unknown, although it has been shown to favor asymmetric divisions, maintaining a population of pancreatic progenitors [41] . In addition to the commitment of nestin-positive cells to generate islet-like tissue, nestin-expressing cells seem to be involved in the production of exocrine pancreatic cells, vascular endothelial cells and pancreatic stellate cells [42] [43] [44] . These observations indicate that the cells manifest an unexpected plasticity, allowing their adaptation and response to a large variety of niches and culture environments. In fact, the pancreatic multipotent precursors isolated by Seaberg et al. were capable of giving rise to pancreatic or neural lineages, depending on the culture conditions [40] . Mesenchymal-like cells derived from adult human islets displayed the ability to differentiate into hormonepositive aggregates through a phenomenon called reversible epithelial-to-mesenchymal transition, in which the derived mesenchymal cells expressed nestin [45] . In fact, pancreas development results from the transitions and signal exchange between epithelium and mesenchyme [46] . However, such as mechanism has been questioned by recent reports indicating that mesenchymal cells present in pancreas are from mesenchymal origin [47] [48] [49] [50] . Although these cells are not the source for new β-cells, further manipulations in vitro could result in the generation of functional islet cells [51] . Thus, it seems that the pancreatic mesenchymal stem cell population is heterogeneous, bearing nestin-positive and negative cells and exhibiting a high degree of plasticity. In any case, more work is necessary to reveal the exact function and nature of pancreatic mesenchymal cells during adult life and their real contribution to islet turnover and regeneration.
Alternatively to mesenchyme and duct, exocrine acinar cells could provide progenitors capable of differentiating into insulin-secreting cells [52] . However, the exact origin of these precursor cells has been questioned [53] .
Finally, another source for obtaining pancreatic β-cells is by self-replicating mechanisms. This has been demonstrated by convincing cell-tracing experiments, although the experimental design was not specifically created to search for pancreatic precursors [54] . Most likely, the β-cell replication could be the operating mechanism in normal pancreas turnover, as reflected by the low BrdU (bromo-deoxyuridine) labeling (0.2%) [55] . However, the pancreas is capable of displaying some degree of plasticity towards specific physiological and pathological situations, thereby increasing its turnover rate [56] . Nevertheless, when the damage surpasses the repository capacity of the β-cell, this population becomes incapable of accomplishing its physiological function in maintaining circulating nutrient homeostasis. This occurs in type 1 diabetes, where the rate of β-cell destruction cannot be compensated by the replacement of β-cells by replication and/or pancreatic precursor self-renewal. Indeed, when anti-islet autoimmunity is controlled by Freund's adjuvant injection, allogenic splenocytes or lisofylline, new islet formation can be evidenced and even reinforced in the presence of exendine-4 in diabetic animal models [57, 58] .
At the present, the studies previously cited prove that the pancreatic tissue exhibits sufficient plasticity to produce islets; however these studies require a further optimization in certain areas. For example, it is necessary to increase the intracellular content of insulin, which at the moment is too low to be used in therapeutic approaches. In this context, the insulin secretion experiments indicate that improvements are also necessary in order to better adjust the hormone secretion in response to extracellular glucose demands. The identification of islet progenitors and the design of drugs to stimulate their differentiation, either in vivo or in vitro, would also represent a key challenge in this field. Therefore, it is tempting to speculate that discrete portions of pancreatic tissue could be removed from the patient, expanded, differentiated, manipulated to increase insulin production and finally re-implanted, overcoming the problems related to immune rejection. In addition, these approaches open new ways to exploit cadaveric pancreata, envisaging the possibility of obtaining additional endocrine tissue from ducts or from pre-existing islet-precursors and even β-cells.
Extrapancreatic stem cells
The constraints imposed by pancreatic tissue in terms of identifying pancreatic precursor/s suggest the possibility of using better characterized sources of ASCs. In this sense, bone marrow contains a stem cell reservoir in the adult organism, in which cell plasticity is wider than expected, thereby going beyond blood and bone renewal. Dr. Verfaillie´s laboratory has isolated a rodent multipotent cell side population from bone marrow, called MAPCs (Multipotent Adult Progenitor Cells). These ASCs can be expanded in vitro and differentiated to different lineages that are positive for ectoderm, mesoderm and endoderm markers [59] .
Pancreas derives from endoderm during embryonic development. Certain reports have claimed in vivo pancreas repopulation using highly purified bone marrow stem cells [60] .
In vitro experiments using bone marrow mesenchymal stem cells demonstrate the potential of these cells to differentiate into pancreatic precursors [61] . This transdifferentiation process can be favored by culturing the cells in the presence of histone-deacetylating agents, such as trichostatin A. This compound, together with specific culture conditions, affects chromatin architecture, allowing access to transcription factors that can commit the cells to the pancreatic pathway [62] . Furthermore, human bone marrow mesenchymal cells transfected with DNA constructs coding for key transcription factors involved in endocrine pancreas development and cultured in islet-conditioned medium were capable of expressing the insulin gene [63] . However, other reports failed to obtain pancreatic precursors from these cells [64, 65] , favoring a prominent role in pancreas regeneration for bone marrow-derived stem cells by new vasculature formation [33, [66] [67] [68] . Although there is much work to be performed, it seems that extracellular signals are instrumental in directing bone marrow stem cells to different cell fates, including neovasculature (which seems to be the prominent pathway in vivo), pancreatic-like endocrine structures or neuroendocrine cells, which can be induced by using specific culture medium. In addition, the existence of a heterogeneous population of stem cells inside bone marrow with broad range of plasticity has to be considered further. Interestingly, mesenchymal stem cells from adipose tissue present many similarities with bone marrow mesenchymal stem cells. The culture of these cells in the presence of bFGF (basic Fibroblast Growth Factor) induced islet gene expression [69] . Taken together, these reports indicate a broad differentiation potential for mesenchymal cells, isolated from either bone marrow or adipose tissue, which deserves to be explored in more detail.
In this context, human monocytes isolated from peripheral blood and incubated in the presence of certain cytokines became differentiated into insulin-producing cells. Transplantation of the resulting cells under the kidney capsule of diabetic mouse models resulted in euglycemia over a very short period of time, before immunological rejection [70] . It is not clear whether circulating glucose normalization was due to an artifact insulin release due to the cell death as the result of an immune attack. In fact, the amount of C-peptide released in vitro from the obtained cells was very low to envisage such a spectacular recovery. No graft postmortem analysis was performed in order to identify possible in vivo maturation mechanisms that could increase intracellular hormone production. Lastly, the low reproducibility of the assay is another point to be taken into account.
Liver, as well as pancreas, derives from the definitive endoderm. Thus, this organ could provide ASCs as an alternative source to produce insulin-expressing cells. In this sense, it has been described that oval hepatic stem cells are capable of differentiating into insulin-positive cells, hepatocytes and bile duct epithelium [71] . A different liver stem cell population with close similarities to mesenchymal stem cells has been recently isolated. This population expressed the mesenchymal stem cell markers CD29, CD73, CD44, CD90, nestin and vimentin [72] . Expression of other markers indicated that these cells are a different population from oval hepatic stem cells and mesenchymal bone marrow stem cells. These cells displayed the capacity to differentiate into liver and islet-like structures. In this context, hepatic tissue shares many characteristics with β-cells, primarily the nutrient-sensor machinery that includes the glucose transporter GLUT-2 and glucokinase (the first enzyme of the glycolytic pathway), explaining why these cells are a preferential target for ectopic insulin production with minimal bioengineering [73] . This can be achieved by the overexpression of certain transcription factors that are essential for β-cell function such as Pdx1 or NeuroD combined with betacellulin [74, 75] . The hepatic expression of such proteins induces the activation of the insulin gene in liver cells. A recent report described the isolation of progenitor cells from human fetal liver by transfection with a construction coding for the catalytic subunit of the human telomerase gene. Subsequent transfection of these cells with Pdx1 allowed the production of insulinexpressing cells, which were capable of restoring glycemia once transplanted into diabetic animals [76] . One should be aware, however, that the use of Pdx-1 expression vectors for the induction of differentiating exocrine tissue could cause hepatic destruction [75] .
Finally, certain cells of the intestinal epithelium share many functional and phenotypic traits similar to hepatocytes and β-cells. In particular, L-cells that secrete GLP-1 possess the nutrient-sensing machinery, and ectopic insulin expression has been successfully achieved. However, many cell functions, such as regulated insulin secretion, still need substantial improvements [77] .
Although much work remains, these studies open a new possibility of using liver and gut biopsies to generate functional islet-like structures for cell therapy in diabetes. These cells, together with mesenchymal stem cells, could represent an alternative source of ASCs for autotransplantation, overcoming the problematic immune rejection and offering therapeutic alternatives to type 1 diabetic patients. To achieve such an objective, we need to delve inside the molecular mechanisms involved in these differentiation mechanisms.
Embryonic stem cells
Embryonic stem cells (ESCs) represent an alternative source to ASCs. Mouse ESCs can be maintained in an undifferentiated state in culture either by monolayer growth in the presence of LIF, a cytokine of the interleukine-6 family, or by growing over mitotically inactivated fibroblasts. In contrast, human ESCs do not respond to human LIF and subsequently initiate differentiation processes even when cultured on feeder layers [70] . Thus, it is more difficult to maintain human ESCs in a pluripotent state than mouse ESCs. In vitro, the stem cell population coexists along with other precursor populations (mainly committed to ectoderm) which differ in its kinetic division. Over several passages, this precursor population, which displays a rapid proliferation rate, tends to accumulate in the culture, leading to a cell population with restricted plasticity [78] . In addition, precursors accumulate chromosomal aberrations over time, which are responsible for subsequent tumor formation in transplantation protocols [30, 79] (Figure 1) .
To initiate spontaneous differentiation pathways, ESCs are transferred from adherent monolayers to suspension cultures in bacteriological plates in the absence of LIF. Under these conditions, cells form aggregates called embryoid bodies (EBs) that are instrumental in starting differentiation processes [80] (Figure 2) . Markers from the 3 embryonic layers (ectoderm, mesoderm and endoderm), as well as from the primitive endoderm, are expressed in these structures at different culture times (Table 2) . Although the molecular determinants that induce differentiation in EBs are still unknown, it seems that gradients in nutrients, oxygen and growth factors across the EB, as well as intercellular connections, are instrumental in this phase [81] . Insulin expression, along with other pancreatic hormones, has been observed during spontaneous differentiation in EBs as early as 10 − 23 days in culture [82] . However, the fraction of insulin positive cells is less than 2% of the total number of cells [83] . Therefore, the total amount of insulin synthesized is very low to envisage transplantation protocols. In addition, the high amount of BrdU immunostaining observed in certain differentiation protocols supports the tumorigenic potential of these cells, a point that has not been properly addressed because transplantation protocols were not long enough to adequately answer this question [84] . Table 2 Markers of differentiation detected in EBs by RT-PCR.
As previously stated, β-cells derive from the endoderm and acquires its fate through the expression of specific and unique transcription factors and proteins. In this context, it has been accepted that insulin is the distinctive protein of the pancreatic β-cell. For this reason, in vitro strategies use insulin expression, either in mRNA or protein form, for the isolation and/or characterization of insulin-positive populations. This idea has been the rationale behind all bioengineering protocols designed to produce insulin-containing cells from ESCs. However, the intracellular amount of insulin obtained in these strategies is lower than the insulin content detected in mature β-cells [85] [86] [87] .
To address this dilemma, it is first of all necessary to identify the true origin of these low productive insulin-containing cells. We attempted to answer this question by following insulin gene expression during mouse development. The data provided by Dr Herrera (University of Geneva, Switzerland) were obtained from tissue analysis of a double-transgenic mouse that had the ability to express the viral recombinase Cre under the control of the insulin gene promoter. The expression of Cre relieves a transcriptional block in a second transgene that contains the constitutive promoter ROSA-26, driving the expression of the β-galactosidase gene. This strategy allows the labeling of insulinpositive cells by β-gal staining, even in tissues where insulin is transiently expressed. Results obtained in these animals showed β-gal-positive cells in islets as well as in ectodermal tissues such as the hypothalamus and amygdala. These results confirmed the first observation of insulin transgene expression in the nervous system [88] .
Extrapancreatic insulin expression, however, has always been a controversial matter. The role of the hormone in the nervous system has not been fully clarified. Recent work suggested that this protein acts as a growth factor in stages of nervous system development in which insulin-like growth factors (IGFs) are absent [89] . Rodents have two insulin genes (insulin I and II). The insulin I gene is exclusively expressed in the pancreatic tissue, whereas the insulin II gene displays a modest expression in islets, and is fully expressed in the yolk sack and specific neurons [90, 91] . In this context, the regulation of both genes is completely different. The insulin I gene displays regulation by glucose, whereas the insulin II gene is regulated by growth factors present during development. In addition, insulin II gene product is not fully processed due to the lack of protein convertase-2 (PC2) in neuroectodermal tissues, yielding proinsulin as a final protein product. Finally, the amount of hormone found in ectodermal tissues is 1000 times less than the amount of hormone quantified in islets [90, 92] . All this information has to be considered in bioengineering protocols in which the final cell product must mimic as closely as possible the phenotype of the missing cell type. It is clear that ectoderm-derived insulin-producing cells are far from an endoderm-derived β-cell phenotype. It should be mentioned that several factors could be added or modified in these conditions in order to improve the differentiation process. Furthermore, the formation of EBs has been obviated in certain protocols [95] . The part "B" of the figure indicates some marker genes that can be detected by RT-PCR at ESC and EB stages. See the text for more details. Bars: 100 μm.
All these considerations drive us to take in account the real origin of insulin-producing cells obtained in bioengineering in vitro protocols. Therefore, the presence of endodermal derived cells is a possibility that deserves to be explored. However, this issue is difficult to address in protocols via EBs, since the resulting population originates from different embryonic germ layers. This is also a very difficult point to resolve in insulin-producing cells obtained from human stem cells, since humans have only one insulin gene.
Recently, D'Amour published a protocol to enrich human ESC cultures in cells committed to definitive endoderm by adding activin A to the monolayer culture and subsequent low serum environment. The resulting cell population was purified by cell sorting using the CXCR4 cell membrane receptor. The process was monitored by analyzing the relative expression of specific gene markers, since many genes present in definitive endoderm are also expressed in neuroectoderm and primitive-visceral-parietal endoderm [93] . Another important observation is that definitive endoderm seems to arise, at least in vitro and in mouse ESCs, from a mesendodermal precursor that expresses brachyury and goosecoid, followed by Sox17 [93, 94] .
In vitro differentiation protocols
The development of insulin-containing cells from stem cells is a complex process with many problems that remain to be resolved. However, certain protocols are adding key points that are helping to establish a definitive protocol. In this context, a coaxial protocol has been developed in Baetge´s laboratory [95] . Despite the fact that the final cell product still differs from an adult β-cell, this is the first report in which intracellular insulin levels are close to those found in differentiated β-cells. However, different approaches have been tested by several groups in ESCs as well as in ASCs (Table 3) . These have been classified in two categories: spontaneous differentiation combined with selection strategies, and directed differentiation that uses coaxial and reprogramming technology.
Spontaneous differentiation
Spontaneous differentiation combined with gating selection methods allows the isolation of cell populations that express a specific gene, i.e. insulin. To this end, specific DNA constructs are used in order to confer resistance to antibiotics or allow the expression of fluorescence proteins (i.e. EGFP: Enhanced Green Fluorescent Protein) under the control of β-cell specific promoters. Aside from insulin-positive cells [96] , this simple genetic selection method has been applied to obtain other cell types, such as cardiomyocytes and neuronal-like cells [97] [98] [99] .
The strategy applied to obtain insulin-secreting cells from ESC [96] consisted of a double-selection protocol based on the resistance to two antibiotics: hygromycin and neomycin. The transfected DNA construct contained the hygromycin resistance gene under the control of the phosphoglycerate kinase constitutive promoter, thereby allowing the selection of single clonal cell lines.
The second selection strategy was based on the expression of the neomycin resistance gene under the control of the insulin gene regulatory regions. Thus, the cells expressing insulin were functionally capable of expressing the neomycin resistance protein and survive when neomycin was added to the culture medium. The generation of insulin-producing cells during the differentiation process could be monitored by using a construct coding for a fusion protein of the β-galactosidase enzyme and the neomycin-resistance marker.
In this case, the lineage specific promoter regulates both the neomycin-resistance gene and the marker gene lacZ, which can be visualized easily during the different stages of differentiation [82] . However, the main disadvantage of this strategy is the inability to discriminate between ectodermal and endodermal-derived insulin producing cells (Figure 1) .
One alternative to the generation of highly differentiated insulin producing cells would be to obtain precursor cells committed to differentiate into β-cells. Recently, it has been demonstrated that gating technology also allows the use of constructs that are functionally active during intermediate stages of embryonic development, forcing in this way the derivation of islet precursor cells.
Based on this idea, an alternative protocol has been developed [100] using the Nkx6.1 gene promoter controlling neomycin resistance. Nkx6.1 is a transcription factor involved in the expansion of β-cell precursors during endocrine pancreas development [101] . The selection with neomycin, together with specific culture conditions (the presence of nicotinamide, anti-sonic hedgehog and conditioned media from pancreatic buds), produced a pure population of cells co-expressing insulin as well as genes coding for key β-cell proteins, including some transcription factors and proteins of the glucose-sensing machinery such as glucokinase, GLUT-2 and Sur-1. These particular culture conditions resulted in cells that responded to increasing concentrations of extracellular glucose in terms of insulin secretion. Subsequent transplantation into the kidney capsule restored normoglycemia for 3 weeks in streptozotocin-diabetic mice and reverted to hyperglycemia once the graft was removed. This new strategy still offers low but reproducible amounts of intracellular insulin content which needs to be improved in order to advance towards transplantation trials. Since Nkx6.1 is also expressed in ectodermal-derived precursors, the derivation of different cell populations expressing ectodermal and endodermal insulin is possible [102] .
Directed differentiation
Directed differentiation includes coaxial methodology and cell reprogramming. Coaxial approaches are based on the addition of specific growth factors to the culture medium to drive ESCs or ASCs into insulin-positive cells. Otherwise, cell reprogramming can be achieved by introducing specific proteins into the target cell either directly (cell extracts or purified proteins) or by using specific gene constructions. Table 3 Evaluation of the different approaches used to obtain insulin-positive cells from ESCs and ASCs.
Coaxial methodology
As commented previously, E. Baetge´s group developed an important approach to obtain insulin producing cells [95] . This protocol recapitulates key stages of pancreatic development (Figure 3) , although many aspects of this process in mouse and mainly in humans are still poorly understood. The key point of this strategy is the enrichment of the human ESC population in definitive endoderm precursors, as previously stated by others [103, 104] . At this point, a five-stage differentiation protocol is used, where different compounds are added to the culture medium during each stage. The stages defined in the protocol, and the main compounds used, included primitive gut endoderm (FGF10 + cyclopamine), posterior foregut (FGF10 + cyclopamine + retinoic acid), pancreatic endoderm and endocrine precursors (Notch-pathway inhibitor DAPT + exendin-4), and finally hormone-expressing cells (exendin-4 + IGF1 + HGF (Hepatocyte Growth Factor)). The resulting cells possessed high insulin concentrations, close to those found in mature β-cells, and in some clusters the hormone was coexpressed with glucagon or somatostatin. The cells responded to multiple secretagogues; however they had a low response to extracellular glucose, indicating that these cells resembled fetal pancreatic islets in terms of hormone secretion. An additional five human ESC lines were used with this protocol, demonstrating its reproducibility. It is important to mention that this protocol avoids EB formation, a critical step in differentiation for mouse ESCs towards definitive endoderm and insulin-secreting cells. The elimination of this stage during the differentiation protocol diminishes the spontaneous differentiating cells from other lineages that can contaminate the culture. In addition, this allows a homogeneous access of all growth factors and compounds that were included in the protocol. Although more research needs to be performed, this protocol undoubtedly will help to redefine other protocols and to design new strategies in obtaining insulin-secreting cells from ESCs. Thus, the search for new determinants that can complement and improve this in vitro differentiation process could help in obtaining cells with similar characteristics to pancreatic β-cells. Incubation at certain stages with conditioned medium from pancreatic rudiments or the co-culture with pancreatic buds could help to find new factors that can be added to this protocol [84, 100, 105] .
Another approach developed is based on the idea that nestin-positive cells could correspond to neuronal and endocrine pancreatic precursors, representing an additional example of directed differentiation using the coaxial methodology [87] . This strategy included several components, some of them described by others [96] , in the in vitro differentiation process. These components include ITSFn medium (DMEM/F12 containing insulin, transferrin, selenium and fibronectin) and N2 medium [DMEM/F12 containing B27 supplement, insulin, transferrin, selenium, progesterone and putrescine supplemented with bFGF]. N2 medium allowed the expansion of nestin-positive cells in serum-free conditions. Elimination of bFGF from this medium and the addition of nicotinamide in the last stage favored insulin expression [106] . See the text for more details.
The cell aggregates obtained from nestin-positive cells contained neurons (in the outer layer of the aggregate) tightly associated with insulin-positive cells (15 − 30% of the interior cells). Nevertheless, the estimated insulin content was too low to envisage transplantation trials. Subsequent studies were performed in order to increase the number of insulin-positive cells with respect to neurons and hormone content. Insulin content increased modestly through the addition of phosphoinositide-3-kinase inhibitors (LY294002 or wortmannin) or the secretagogue glucagon-like peptide-1 (GLP-1) in the last stage of the protocol [107, 108] . The introduction of new growth factors, such as KGF (Keratinocyte Growth Factor) and EGF, during the expansion phase of nestin-positive cells and in combination with gating selection strategies also resulted in low amounts of insulin [109, 110] .
Some groups have successfully obtained insulin-positive cells from human ESCs based on the selection of nestin precursors developed in mice [111] . The method was improved by lowering the glucose concentration in a final step of the protocol. However, the coexpression of insulin with other pancreatic endocrine hormones, such as glucagon and somatostatin, suggested that the obtained cells were still in an immature state [112] .
Coaxial methodology has also been used with ASCs. As previously mentioned, the pancreatic ductal epithelium contains some cell types that can differentiate into islets under certain experimental conditions, representing a good example of coaxial strategies [35] . Expansion, differentiation and maturation of ductal cells was performed in DMEM/F12 serum-free medium containing ITS (Insulin + Transferrin + Selenium), KGF (to favor ductal tissue expansion), nicotinamide and 8 mM glucose. Matrigel R (a commercial analogue of the extracellular matrix) was added as a support to allow the formation of CHIB structures [35] .
ASCs from other organs, such as bone marrow or liver, have also been used in coaxial protocols to obtain insulin-producing cells or cells capable of generating the differentiation factors necessary to acquire a β-cell phenotype [59, 60, 66, 67, 71] . Rat oval cells can be isolated from liver and maintained undifferentiated in serum-free medium containing 5 mM glucose and LIF. Transdifferentiation to islet-like structures can be performed by adding 10% serum, increasing glucose concentration (23 mM) and removing LIF from the culture medium.
Altogether, for the coaxial approaches in human or mouse ESCs to be therapeutically viable, it is necessary to optimize the characterization criteria. For instance, insulin staining and its radioimmuno-detection are not robust criteria for endogenous hormone production. In this respect, it has been described that part of the immuno-detected hormone can be taken up from the culture medium into the cells, especially when they enter into apoptosis [113] . In addition, insulin sequestration may inhibit de novo synthesis of the hormone [114] . Exogenous insulin is added in protocols based on the selection of nestin-positive cells and to obtain CHIBs. The serum added to the medium is another source of exogenous bovine insulin. This observation therefore suggests that C-peptide detection, which has to match the concentration of the secreted rodent insulin, together with the presence of insulin mRNA and specific β-cell proteins must be used as more consistent markers for endogenous insulin production.
Cell reprogramming
Certain proteins contain membrane transduction domains that allow access to the intracellular compartment. The most characterized motifs have been described in the Antennapedia transcription factor, protein VP22 from Herpes simplex virus and transactivator TAT from human immunodeficiency virus [115] . In addition, when these domains are covalently attached to proteins, they are capable of transducing from the extracellular milieu to the interior of the cell by the use of a mechanism called retrograde transport. In this mechanism, the external protein is incorporated via endocytosis followed by passage from the internalized vesicle to the cytoplasm. Another mechanism implies the interac-tion of the membrane transduction domain with lipids of the bilayer internalizing the protein through micropores or inverted micelle formation (Figure 4) . This system can be used to introduce proteins (mainly transcription factors) inside certain cell types, allowing their reprogramming to specific cell fates. In this sense, Pdx1 possesses an Antennapedia-like domain which is responsible for the permeation of this transcription factor from the extracellular medium into pancreatic islets and ductal cells, inducing insulin gene expression [116] . In this context, NeuroD, a basic helix-loop-helix transcription factor and regulator of the insulin gene, can be transduced into several cell types by attaching an arginine-lysine-rich transduction domain [109] . Furthermore, neurogenin3 transcription factor fused to a TAT transduction domain favored endocrine differentiation when administered to pancreatic progenitor explants [117] . This interesting technology has many implications in bioengineering protocols. The introduction of transcription factors at the desired concentration into stem cells may allow the in vitro reprogramming towards specific cell types. Modulation of immunocompetence and survival of newly isolated islets could be another interesting application of this technology, improving the quality of the transplantable material. It is important to confirm that the modified protein can perform the same function as the native unmodified protein.
The advantages of the protein transduction technology are low toxicity, the control of the protein concentration that is introduced inside the cell, the combination of paracrine effects together with reprogramming properties, and the non-utilization of gene transfer technology, which is poses ethical limitations on the use of DNA constructs in human tissues [118, 119] .
Equally, proteins can be introduced into cells by using permeabilization protocols. This methodology consists in applying streptolysin O to transiently permeabilized cellular membranes and thereby introducing specific protein extracts into the cells. The extract provides transcription factors that may alter nuclear function, allowing the expression of a specific set of genes [120] . Using this transdifferentiation protocol, fetal rat fibroblasts have been reprogrammed with whole-cell extracts obtained from an insulinoma cell line (INS-1E). The resulting cells (5 − 30%) expressed insulin during 8 − 14 days after permeabilization [121] . Again, this permeabilization strategy can enhance insulin gene expression without requiring DNA constructs, thereby and overcoming the ethic problems posed by genetic manipulation.
On the other hand, the use of gene transfer technology allows the constitutive expression of key transcription factors that are instrumental in β-cell function or development. In this context, transfected ESCs over-expressing Pdx1 or Pax4 were bioengineered to obtain insulin-positive cells [86, 122] . Both proteins are important factors in β-cell differentiation [101] . However, Pax4 expression demonstrated better yields in insulin production in the background of nestin positive-cell selection. Pdx1-enhanced expression may require additional signals to induce insulin gene expression. is covalently attached to the cargo, the protein can enter the cell by: a) pinocytosis and subsequent retrograde transport or vesicle disruption, as well as by b) membrane interactions (including micropore or inverted micelle formation). When the MTD does not establish covalent interactions with the cargo, the protein enters the cell through membrane interactions (c) similar to the process described in b.
As indicated previously, DNA-based strategies have been designed in other cell types distinct from β-cells, by allowing the expression of certain transcription factors that are essential for proper β-cell function such as Pdx1 or NeuroD. In hepatic cells, this resulted in the induction of the insulin gene [71, 74, 75, 123] , offering thereby an interesting use of autotransplantable liver biopsies to generate functional islet-like clusters for cell therapy of diabetes. In a similar fashion, human bone marrow mesenchymal stem cells were infected with adenoviral vectors coding for key transcription factors in endocrine pancreas development (Ipf1, Hlxb9 and FoxA2). The subsequent incubation in islet-conditioned medium resulted in insulin gene expression [63] .
All the described methods indicate that the pathways to in vitro expansion and differentiation to insulin-positive cells are numerous. However, we are still at the beginning and important improvements need to be performed in order to advance in this field.
Conclusions
Although all the published protocols require a further optimization, a reasonable amount of evidence demonstrates that stem cells could be, to varying degrees, a potential source of cells for diabetes treatment in Regenerative Medicine protocols. The final cell product needs to mimic as closely as possible the phenotype and function of mature β-cells in order to assure the appropriate restoration of the lost function in the organism. To this end, the final cell product obtained by these protocols must be characterized not only by the presence of the insulin hormone and C-peptide, but also express the following three functional groups of proteins: (a) the glucose-sensing machinery, (b) the exocytotic apparatus, and (c) the insulin processing proteins. However, this in vitro work represents just the first part. Transplantation of bioengineered cells is most likely to pose new challenges to scientists [22] . Some of them are:
-Appropriate animal models: There are no animal models capable of mimicking 100% the human diabetic pathology [124, 125] . Experimental type 1 diabetes is induced by streptozotocin injection, a drug that specifically destroys β-cells in rodents. Alternative animal models are the non-obese diabetic mouse (NOD) and the biobreeding rat (BB rat). Indeed, the ideal model does not exist since human disease is more multifactorial than in the corresponding animal counterparts. However, experiments in animals are instrumental and mandatory before transferring all the technology to humans. New models of pancreas regeneration and differentiation will be also required in a near future.
-Implantation site: The Edmonton protocol for islet transplantation suggests that the liver through portal vein administration is a good location for the inoculation, since this site assures correct nutrition and oxygen supply [24] . Furthermore, the liver has the same endodermic origin as islets, resulting in an appropriate niche for these cells. Other possibilities that have demonstrated functional capacity in animal models are the renal capsule and spleen [96, 100] . However, these niches in humans seem to be less advantageous for maintaining a transplant for long periods of time. Alternative niches for transplantation should be explored.
-Immune rejection: It is obvious that bioengineered stem cells can be rejected by the recipient. However, alternatives to circumvent this problem are offered by the possibility of making customized tissues by gene manipulation, nuclear transfer and oocyte parthenogenesis. Furthermore, the possibility of stem cells to colonize bone marrow may allow the generation of chimeric lymphocytes, allowing biocompatible implants to remain in the body with no immune rejection [22] . In relation to pancreas regeneration, the majority of the efforts should be to develop the proper therapeutic strategies that are capable of restoring its self-tolerance to pancreatic β-cells [126] . It is important to point out that this problem is absent in ASCs, provided that donor and recipient are the same person.
-Implant survival: The implant must be placed in a well-irrigated site with an adequate oxygen and nutrient supply to allow correct cell turnover. Implant survival will depend on anti-necrotic and anti-apoptotic mechanisms as well as on controlled self-renewing capacity. Apoptosis in pancreatic β-cells usually occurs through two main mechanisms that operate to different degrees in type 1 diabetes: the pathway of NO/inducible NO synthase and through mitochondrial dysfunction [22] . On the other hand, uncontrolled cell divisions could facilitate tumor development. Taking this information into account, transplanted cells could be purified and manipulated accordingly in order to establish a properly regulated cell cycle [127] , allowing proper survival and turnover.
-Biosafety mechanisms: Such strategies would allow graft elimination in the case of non-function or tumor formation. This can be achieved with biosafety DNA constructs such as the Herpes simplex virus thymidine kinase gene. Thymidine kinase is sensitive to antiviral pharmacological agents such as ganciclovir or acidovir, resulting in cell death, as has been demonstrated in gene therapy protocols [22] .
-In vivo differentiation process. This is still an open field of research. Experience in animals suggests that transplanted bioengineered cells may allow additional differentiation processes to occur in vivo if they are transplanted into a favorable niche [100] . More information will be necessary in order to design strategies exploiting this interesting possibility.
In conclusion, we are beginning to consider the use of stem cells in the treatment of diabetes. There is still much work to be performed before new bioengineered β-cells will be created for clinical trials. The emerging technology will help to achieve this goal, but we need to investigate more of the basic biology of stem cells and the determinants that govern autoreplication and differentiation in order to improve on the actual protocols.
